Member access

4-Traders Homepage  >  Shares  >  Amex  >  CEL-SCI Corporation       US1508374097

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine, is being developed as a potential therapeutic agent... 
More about the company
Financials ($)
Sales 2014 0,23 M
EBIT 2014 -25,2 M
Net income 2014 -
Debt 2014 -
Yield 2014 -
Sales 2015 0,26 M
EBIT 2015 -26,9 M
Net income 2015 -
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 256x
Capi. / Sales 2015 228x
Capitalization 59,2 M
More Financials
Latest news on CEL-SCI CORPORATION
12/11 CEL SCI : Expands Pivotal Phase III Immunotherapy Head and Neck Cancer Trial
12/08 CEL SCI : NEW STORY CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and..
12/08 CEL SCI : Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial..
12/02 CEL SCI : NEW STORY CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Ca..
12/02 CEL SCI : Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Tri..
11/06 CEL SCI : Enlists 22 Patients During October in Phase III Immunotherapy Head and..
11/05 CEL SCI : Announces Closing of Public Offering for Gross Proceeds of $6 Million
11/05 CEL SCI : Updates on Closing of Public Offering for Gross Proceeds
More news
Sector news
4h ago ACTELION : submits US FDA New Drug Application for selexipag (Uptravi) in patien..
6h ago MEDIVATION : Exercises License Option for Pidilizumab
9h ago MONDAY'S ETF MOVERS : Eem, bbh
More sector news
Comments 
Advertisement
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF